MINI FUTURE LONG - AMGEN | Real-time Bid/Ask 04:40:48 20/05/2024 pm IST | ||
| 9.73 EUR / 9.85 EUR | +0.31% |
|
| Current month | +52.02% | ||
| 1 month | +78.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 9.77 | +0.10% |
| 17/24/17 | 9.76 | -2.40% |
| 16/24/16 | 10 | -3.01% |
| 15/24/15 | 10.31 | +7.51% |
| 14/24/14 | 9.59 | +3.12% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 02:49 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MD0EWV |
| ISIN | DE000MD0EWV2 |
| Date issued | 09/12/2021 |
| Strike | 206.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.3 € |
|---|---|
| Lowest since issue | 1.73 € |
| Spread | 0.13 € |
| Spread % | 1.32% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.5
USD
Average target price
314.6
USD
Spread / Average Target
+0.70%
- Stock Market
- Certificates
- Certificat
